Technical Analysis for KZIA - Kazia Therapeutics Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical KZIA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Expansion Breakdown | Bearish Swing Setup | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | -4.90% | |
| Narrow Range Bar | Range Contraction | -4.90% | |
| NR7 | Range Contraction | -4.90% | |
| Multiple of Ten Bullish | Other | -4.90% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 1 ATR | about 6 hours ago |
| Down 5% | about 7 hours ago |
| Down 3% | about 7 hours ago |
| Fell Below Previous Day's Low | about 7 hours ago |
| Lower Bollinger Band Support | about 7 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 01/23/2019
Kazia Therapeutics Limited Description
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer ATM Cancer Treatments Chemotherapy Ovarian Cancer Blastoma Cancer Treatment Cancer Cell Glioma Neuroblastoma Cytoskeleton Novogen Pharmaceutical Research Diffuse Intrinsic Pontine Glioma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.85 |
| 52 Week Low | 2.55 |
| Average Volume | 115,365 |
| 200-Day Moving Average | 8.78 |
| 50-Day Moving Average | 11.11 |
| 20-Day Moving Average | 10.59 |
| 10-Day Moving Average | 10.19 |
| Average True Range | 0.66 |
| ADX | 19.16 |
| +DI | 13.47 |
| -DI | 29.32 |
| Chandelier Exit (Long, 3 ATRs ) | 10.61 |
| Chandelier Exit (Short, 3 ATRs ) | 11.08 |
| Upper Bollinger Band | 11.56 |
| Lower Bollinger Band | 9.61 |
| Percent B (%b) | -0.05 |
| BandWidth | 18.46 |
| MACD Line | -0.45 |
| MACD Signal Line | -0.34 |
| MACD Histogram | -0.112 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.00 | ||||
| Resistance 3 (R3) | 11.03 | 10.56 | 10.76 | ||
| Resistance 2 (R2) | 10.56 | 10.18 | 10.55 | 10.67 | |
| Resistance 1 (R1) | 10.04 | 9.95 | 9.81 | 10.01 | 10.59 |
| Pivot Point | 9.57 | 9.57 | 9.45 | 9.56 | 9.57 |
| Support 1 (S1) | 9.05 | 9.19 | 8.82 | 9.03 | 8.45 |
| Support 2 (S2) | 8.58 | 8.96 | 8.57 | 8.37 | |
| Support 3 (S3) | 8.06 | 8.58 | 8.28 | ||
| Support 4 (S4) | 8.04 |
